Needham still positive on Sarepta as competitive landscape is improved

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Needham is apparently out reiterating a Buy rating on Sarepta Therapeutics (SRPT), price target is $57.

Chad Messer says "drisapersen's failure may lead to skepticism on the exon-skipping approach in general, [but Needham] remains confident in eteplirsen's efficacy and believes [the drisapersen news] improves the competitive situation."

See previous coverage